- Home
- STTK vs SCPH Comparison
STTK vs SCPH Comparison
Compare STTK & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SCPH
- Stock Information
- Founded
- STTK 2016
- SCPH 2013
- Country
- STTK United States
- SCPH United States
- Employees
- STTK N/A
- SCPH N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- SCPH Health Care
- Exchange
- STTK Nasdaq
- SCPH Nasdaq
- Market Cap
- STTK 83.8M
- SCPH 299.0M
- IPO Year
- STTK 2020
- SCPH 2017
- Fundamental
- Price
- STTK $1.92
- SCPH $5.63
- Analyst Decision
- STTK Hold
- SCPH Buy
- Analyst Count
- STTK 6
- SCPH 3
- Target Price
- STTK $2.67
- SCPH $12.00
- AVG Volume (30 Days)
- STTK 1.6M
- SCPH 2.3M
- Earning Date
- STTK 11-13-2025
- SCPH 11-12-2025
- Dividend Yield
- STTK N/A
- SCPH N/A
- EPS Growth
- STTK N/A
- SCPH N/A
- EPS
- STTK N/A
- SCPH N/A
- Revenue
- STTK $2,997,000.00
- SCPH $49,969,000.00
- Revenue This Year
- STTK N/A
- SCPH $108.95
- Revenue Next Year
- STTK N/A
- SCPH $78.30
- P/E Ratio
- STTK N/A
- SCPH N/A
- Revenue Growth
- STTK N/A
- SCPH 107.79
- 52 Week Low
- STTK $0.69
- SCPH $1.94
- 52 Week High
- STTK $3.95
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- STTK 72.13
- SCPH 64.37
- Support Level
- STTK $1.68
- SCPH $4.33
- Resistance Level
- STTK $2.04
- SCPH $5.62
- Average True Range (ATR)
- STTK 0.19
- SCPH 0.05
- MACD
- STTK 0.09
- SCPH 0.01
- Stochastic Oscillator
- STTK 89.29
- SCPH 93.75
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.